A Novel Adjuvant System for High‐Efficiency Subunit Vaccines Against Porcine Deltacoronavirus

Read full text Summarise with VIRAT
Authors: Shuangyuan Xu, Shuqing Zhao, Ziyi Niu, Xiaofeng Xue, Wei Chun WANG, Rongli Guo, Lili Ren, Bin LI, Jizong Li
Cited by: 0
References: 15

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Summary The immunopotentiation efficacy of polydimethyl diallyl ammonium chloride (pDMDAAC) nanoparticles (NPs) as an adjuvant for the spike (S) protein subunit vaccine of porcine deltacoronavirus (PDCoV) was investigated, with particular emphasis on the combination of the NPs with the STING agonist cGAMP. Following dorsal subcutaneous immunization in mice, ELISA and virus neutralization assays revealed that the combination of pDMDAAC NPs and cGAMP (S‐pDMDAAC–cGAMP) significantly enhanced PDCoV‐specific IgG antibody titers and neutralizing antibody (nAb) potency in serum compared with the S protein alone. Further analysis via CCK‐8 assay indicated there was markedly augmented splenic lymphocyte proliferation capacity in the S‐pDMDAAC–cGAMP group, indicating robust cellular immune activation. Cytokine profiling showed elevated secretion levels of IFN‐γ, IL‐4, and TNF‐α in splenocytes, while flow cytometric analysis revealed increased proportions of CD3 + CD4 + and CD3 + CD8 + T lymphocytes, accompanied by elevated B‐cell populations in inguinal lymph nodes and spleen. These results collectively indicated that pDMDAAC NPs substantially potentiate both humoral and cellular immunity toward the PDCOVID‐19S protein and cGAMP amplified this adjuvant effect.

Fields of Study & Subjects

Animal Virus Infections Studies SARS-CoV-2 and COVID-19 Research Immunotherapy and Immune Responses

Publication details

Journal / source
Transboundary and Emerging Diseases
Volume
2026
Issue
1
Pages
5883013
Publication date
1 January 2026
Language
EN